Your claim would generally target the company, not the prescribing physician, unless theres clear evidence of medical negligence
A true inspiration
This enzyme belongs to the family of transferases, specifically those acyltransferases transferring groups other than aminoacyl groups
Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months
29.Friml, J., Benkova, E., Blilou, I., Wisniewska, J., Hamann, T., Ljung, K., Woody, S., Sandberg, G., Scheres, B., Jurgens, G., and Palme, K
Meanwhile, Biocon, Cipla, Sun Pharma, Lupin, and Alkem are all in various stages of development or filing